Regenxbio (RGNX) Change in Accured Expenses (2014 - 2025)

Regenxbio's Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $3.2 million for Q4 2025.

• In Q4 2025, Change in Accured Expenses rose 377.0% year-over-year to $3.2 million; the TTM figure through Dec 2025 stood at $229000.0 (up 108.78% YoY), while the FY2025 annual figure was $229000.0, up 108.78% from the prior year.
• Change in Accured Expenses was $3.2 million for Q4 2025 at Regenxbio, up from -$420000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $34.3 million in Q2 2022 to a low of -$33.6 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged $218200.0 across 5 years, with a median of $53500.0 in 2021.
• Biggest YoY gain for Change in Accured Expenses was 51800.0% in 2022; the steepest drop was 69565.79% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $29.9 million in 2021, then plunged by 212.2% to -$33.6 million in 2022, then soared by 115.16% to $5.1 million in 2023, then sank by 122.82% to -$1.2 million in 2024, then soared by 377.0% to $3.2 million in 2025.
• The last three Change in Accured Expenses figures came in at $3.2 million (Q4 2025), -$420000.0 (Q3 2025), and $11.9 million (Q2 2025), per Business Quant data.